Similarly, a combined apigenin/specific flavonoid with letrozole (an aromatase inhibitor) may mitigate some of the serious side effects of letrozole (e.g., joint pain and nephrotoxicity) [69,70] and benefit breast cancer patients with ER+. Here, CYP19A1 is linked to breast carcinoma.